Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide

Drugs

Volumn 75, Issue 9, 2015, Pages 931-933

  Krentz, Andrew J ^a   Fujioka, Ken ^b   Hompesch, Marcus ^a  

^a Profil Institute for Clinical Research   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMFEPRAMONE; BENFLUOREX; BENZPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; LIRAGLUTIDE; LORCASERIN; MAZINDOL; METHAMPHETAMINE; PHENDIMETRAZINE; PHENMETRAZINE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PHENYLPROPANOLAMINE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT;

ANTIOBESITY THERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG RECALL; DRUG SAFETY; DRUG THERAPY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; OBESITY; POSTMARKETING SURVEILLANCE; WEIGHT CONTROL; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; DRUG APPROVAL; HUMANS; OBESITY;

EID: 84930929005     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0404-z     Document Type: Editorial

References (11)

1. Cheung B, Cheung TT, Samranayake NS. Safety of antiobesity drugs. Ther Adv Drug Safety. 2013;4:171-81.
2. Krentz AJ FK, Hompesch M. Evolution of pharmacological obesity treatments: Focus on the history of adverse side-effect profiles. Pharmaco Economics (in press).
3. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes. 2011;2011:179674.
4. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905-17.
5. Rodgers RJ, Tschop MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Models Mech. 2012;5:621-6.
6. Food and Drug Administration. Guidance for industry developing products for weight management. 2007. http://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf. Accessed 5 Mar 2015.
7. Colman E. Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation. 2012;125:2156-64.
8. Sonnenberg G, Matfin G, Reinhardt RR. Drug treatments for obesity: where are we heading and how do we get there? Br J Diabetes Vasc Dis. 2007;7:111-8.
9. Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis. 2014;5:135-48.
10. Astrup A, Rossner S, Finer N, Van Gaal L. Obesity in Europe - does anybody care? Expert Opin Pharmacother. 2013;14:971-3.
11. Elangbam CS. Review paper: current strategies in the development of anti-obesity drugs and their safety concerns. Vet Pathol. 2009;46:10-24.